Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Recruiting

Phase 3

Sonrotoclax & ZanubrutinibTesting the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT07321652

Conditions

Chronic Lymphocytic Leukemia

Small Lymphocytic Leukemia

Eligibility Criteria

Sex: All

Age: 65+

Healthy Volunteers: Not accepted

Interventions

Zanubrutinib

Sonrotoclax

Computed Tomography

Bone Marrow Aspiration

Biospecimen Collection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-20. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2026-06-16.